Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 6/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.63 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698956 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7435677 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7442528 | 0.89 | PDE4A (0.80) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7432993 | 0.89 | PDE4A (0.80) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7434132 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7436868 | 0.86 | PDE4A (0.76) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7441893 | 0.85 | PDE4A (0.74) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7450694 | 0.85 | PDE4A (0.74) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7439484 | 0.83 | PDE4A (0.71) | PDE4APDE4BPDE4DPDE4CTOP1 | |
| SCHEMBL7439997 | 0.83 | PDE4A (0.71) | PDE4APDE4BPDE4DPDE4CTOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| US-20230395254-A1 | Nausea and Vomiting Management System | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-07 | — | — | US | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| WO-2022025035-A1 | NAUSEA AND VOMITING MANAGEMENT SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | PDE4A 323/4885PDE4B 477/4885PDE4D 548/4885 |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | PDE4A 238/4885PDE4B 299/4885PDE4D 257/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | PDE4A 142/4885PDE4B 179/4885PDE4D 215/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | PDE4A 152/4885PDE4B 185/4885PDE4D 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.